The U.S. Food and Drug Administration said on Tuesday it has sent warning letters to four companies for selling unapproved versions of GLP-1 drugs including semaglutide and tirzepatide, the active ingredients in popular diabetes and weight-loss drugs.
The letters were issued to Xcel Peptides, Swisschems, Summit Research, and Prime Peptides last week after the U.S. health regulator conducted a review of their respective websites in October.
The websites indicate that their products are labeled as “research use only” or “not for human consumption or clinical use.” However, evidence gathered by the FDA establishes that these products are actually intended to be used as drugs for humans….